Delmer Dee Raibourn III
@Avidity Partners Management Lp
Latest period2024 - Q3ReportedManaged Assets$1.96BTotal holdings81
Assets growth rate-16.7%Assets growth rate (2-Q avg)-20.41%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Avidity Partners Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 81 positions.
Assets under management
The assets under management (AUM) of Avidity Partners Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.96B in assets, with a quarterly growth rate of -16.7% and a 2-quarter average growth rate of -20.41%. The portfolio is managed by Delmer Dee Raibourn III, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
CIThe Cigna Group
| 0% | $60.99M 184,500 shares@ $330.57 avg price | Exited |
ALNYAlnylam Pharmaceuticals Inc
| 0% | $53.946M 222,000 shares@ $243.0 avg price | Exited |
REGNRegeneron Pharmaceuticals
| 0% | $50.449M 48,000 shares@ $1051.03 avg price | Exited |
MRKMerck & Co Inc
| 0% | $40.235M 325,000 shares@ $123.8 avg price | Exited |
UTHRUnited Therapeutics Corp Del
| 0% | $35.041M 110,000 shares@ $318.55 avg price | Exited |
LNTHLantheus Hldgs Inc
| 0% | $23.284M 290,000 shares@ $80.29 avg price | Exited |
PCVXVaxcyte Inc
| 0% | $21.445M 284,000 shares@ $75.51 avg price | Exited |
JSPRJasper Therapeutics Inc
| 0% | $17.751M 782,000 shares@ $22.7 avg price | Exited |
LEGNLegend Biotech Corp
| 0% | $17.627M 398,000 shares@ $44.29 avg price | Exited |
GILDGilead Sciences Inc
| 0% | $17.496M 255,000 shares@ $68.61 avg price | Exited |